Limited evidence for diagnosing and treating “non-criteria obstetric antiphospholipid syndrome”

Thrombosis and Haemostasis

Volumn 114, Issue 3, 2015, Pages 651-652

  de Jesus, Guilherme Ramires ^a   Levy, Roger Abramino ^a   Porter, T Flint ^b,c   Branch, D Ware ^b,c  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c INTERMOUNTAIN HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; LOW MOLECULAR WEIGHT HEPARIN; ANTICOAGULANT AGENT; PHOSPHOLIPID ANTIBODY;

ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; CHROMOSOME ABERRATION; FERTILIZATION IN VITRO; HUMAN; INFERTILITY; LETTER; LOW DRUG DOSE; META ANALYSIS (TOPIC); PREGNANCY OUTCOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPONTANEOUS ABORTION; SYSTEMATIC REVIEW (TOPIC); BLOOD; FEMALE; PREGNANCY; PREGNANCY COMPLICATIONS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84940702545     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-02-0156     Document Type: Letter

References (13)

1. Arachchillage DR, Machin SJ, Mackie IJ, et al. Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. Thromb Haemost 2015; 113: 13-19
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306
3. de Jesus GR, Agmon-Levin N, Andrade CA, et al. A14th International Congress on AntiphospholipidAntibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev 2014; 13: 795-813
4. Mekinian A, Loire-Berson P, Nicaise-Roland P, et al. Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels. J Reprod Immunol 2012; 94: 222-226
5. Simchen MJ, Dulitzki M, Rofe G, et al. High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet Gynecol Scand 2011; 90: 1428-1433
6. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100: 408-413
7. Laskin CA, Spitzer KA, Clark CA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009; 36: 279-287
8. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-1589
9. Rai R, Cohen H, Dave M, et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997; 314: 253-257
10. Sugiura-Ogasawara M, Ozaki Y, Katano K, et al. Abnormal embryonic karyotype is the most frequent cause of recurrent miscarriage. Hum Reprod 2012; 27: 2297-2303
11. Grande M, Borrell A, Garcia-Posada R, et al. The effect of maternal age on chromosomal anomaly rate and spectrum in recurrent miscarriage. Hum Reprod 2012; 27: 3109-3117
12. de Jong PG, Kaandorp S, Di Nisio M, et al. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database Syst Rev 2014; 7: CD004734
13. Practice Committee of American Society for Reproductive Medicine. Anti-phospholipid antibodies do not affect IVF success. Fertil Steril 2008; 90 (5 Suppl): S172-173.